Thông tin thuốc gốc
Chỉ định và Liều dùng
Type 2 diabetes mellitus
Adult: As monotherapy or in combination with other antidiabetic agents: Initially, 100 mg once daily, may be increased to 300 mg once daily if necessary.
Nhóm bệnh nhân đặc biệt
Patient taking UGT inducers (e.g. rifampicin, phenytoin, phenobarbital, ritonavir, St. John’s wort): 300 mg once daily, as tolerated.
Suy thận
eGFR 45-<60 mL/min/1.73 m2: Max: 100 mg once daily. eGFR <45 mL/min/1.73 m2, ESRD, patients on haemodialysis: Contraindicated.
Suy gan
Severe (Child-Pugh class C): Not recommended.
Cách dùng
May be taken with or without food. Best taken before the first meal of the day.
Chống chỉ định
Renal impairment (eGFR <45 mL/min/1.73 m2), ESRD, or patients on haemodialysis. Lactation.
Thận trọng
Patients with history of hypotension and genital mycotic infection; risk factors for amputation (e.g. prior amputation, peripheral vascular disease, neuropathy, diabetic foot ulcers); CV disease, elevated haematocrit level, risk factors predisposing to ketoacidosis (e.g. pancreatic insulin deficiency, history of pancreatitis or pancreatic surgery; reduction in insulin dose, caloric restriction, severe dehydration, acute medical illness, alcohol abuse, extreme stress event); risk factors for acute renal injury (e.g. hypovolaemia, chronic renal insufficiency, CHF, concomitant use of antihypertensive agents or NSAIDs). Uncircumcised males. Not intended for treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Temporarily discontinue therapy at least 3 days prior to surgery. Renal (eGFR 45-<60 mL/min/1.73 m2) and severe hepatic impairment. Elderly. Pregnancy.
Tác dụng không mong muốn
Significant: Bone fracture, hypersensitivity reactions (e.g. angioedema, anaphylaxis), genital mycotic infections (e.g. vulvovaginal candidiasis, balanitis, balanoposthitis), hypotension, hyperkalaemia, UTI (including urosepsis and pyelonephritis), acute renal injury, hypovolaemia, lower limb amputation (mainly of the toe and midfoot).
Gastrointestinal disorders: Constipation, nausea.
Investigations: Increased haematocrit, BUN, creatinine, LDL cholesterol.
Metabolism and nutrition disorders: Hypoglycaemia (in combination with insulin or sulfonylurea), increased thirst, dyslipidaemia.
Renal and urinary disorders: Polyuria or pollakiuria.
Reproductive system and breast disorders: Vulvovaginal pruritus.
Potentially Fatal: Diabetic ketoacidosis. Rarely, necrotising fasciitis of the perineum (Fournier’s gangrene).
Thông tin tư vấn bệnh nhân
Adhere to preventive foot care as advised by your physician.
Chỉ số theo dõi
Monitor blood glucose and HbA1c (at least twice yearly in patients with stable glycaemic control; quarterly in patients not meeting treatment goals); renal function at baseline and periodically during treatment; serum K periodically (in patients with renal impairment). Assess volume status (e.g. haematocrit, electrolytes, blood pressure) and correct depletion prior to therapy, if necessary. Monitor for new pain, tenderness, sores, ulcers, and infections in the legs and feet; signs and symptoms of ketoacidosis (e.g. nausea, vomiting, abdominal pain, shortness of breath, malaise), hypersensitivity reactions, genital mycotic infections, UTI. Confirm diagnosis of ketoacidosis by measuring blood ketones and arterial pH.
Tương tác
May decrease serum concentration with UGT inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine, ritonavir). Enhanced hypoglycaemic effects of insulin and insulin secretagogues (e.g. sulfonylureas). May reduce absorption with colestyramine. May enhance hypotensive effects of diuretics. May increase the serum concentration of digoxin.
Tương tác với thức ăn
May decrease serum concentration with St. John’s wort.
Ảnh hưởng đến kết quả xét nghiệm
May cause positive result for urine glucose test. May interfere with 1,5-anhydroglucitol (1,5-AG) assay.
Tác dụng
Description: Canagliflozin is a reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2), the main site of filtered glucose reabsorption in the renal proximal convoluted tubules. This reduces reabsorption of filtered glucose and lowers renal threshold for glucose, resulting in increased urinary glucose excretion, thus reducing plasma glucose concentrations.
Onset: Within 24 hours (dose-dependent).
Duration: Suppression of renal threshold for glucose: 24 hours.
Absorption: Absorbed from the gastrointestinal tract. Bioavailability: Approx 65%. Time to peak plasma concentration: 1-2 hours.
Distribution: Plasma protein binding: 99%, mainly to albumin.
Metabolism: Metabolised via O-glucuronidation by uridine diphosphate glucuronosyltransferase (UGT)1A9 and UGT2B4 into 2 inactive O-glucuronide metabolites; undergoes minimal oxidative metabolism by CYP3A4 isoenzyme.
Excretion: Via faeces (41.5% as unchanged drug, 7% as hydroxylated metabolite, 3.2% as O-glucuronide metabolite); urine (approx 33%; 30.5% as O-glucuronide metabolites, <1% as unchanged drug). Terminal elimination half-life: 10.6 hours (100 mg dose); 13.1 hours (300 mg dose).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Canagliflozin, CID=24812758, (accessed on Jan. 21, 2020)

Bảo quản
Store between 15-30°C.
Phân loại MIMS
Thuốc trị đái tháo đường
Phân loại ATC
A10BK02 - canagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Canagliflozin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 02/04/2020.

Buckingham R (ed). Canagliflozin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 02/04/2020.

FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in The Blood and Serious Urinary Tract Infections. U.S. FDA. Accessed 02/04/2020.

Invokana Tablet, Film Coated (Janssen Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 02/04/2020.

Joint Formulary Committee. Canagliflozin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 02/04/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Canagliflozin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in